Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 72

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 72
---
4,139 thousand, or 1,610.5%, compared to Predecessor’s $257 thousand for the same period. The increase was primarily
attributable to Successor’s share-based payment compensation, Successor’s salaries and related expenses and Successor’s
professional services for such period compared to no such expenses in the Predecessor for the same period.

<div align='center'>42</div>

Operating Loss

As a result of the foregoing, Successor’s
and Predecessor’s operating loss totaled $5,567 thousand for the period commencing January 1, 2024 through July 23, 2024, representing
an increase of $4,148 thousand, or 292.3%, compared to Predecessor’s $1,419 thousand for the same period.

Financing expense (income), Net

Successor’s and Predecessor’s recognized
financing income, net of $155 thousand for the period commencing January 1, 2024 through July 23, 2024, representing a decrease of $157
thousand, or 7,850.0%, compared to Predecessor’s finance expense, net of $2 thousand for the same period. The decrease was primarily
attributable to Successor’s interest income from deposit and Successor’s higher exchange rate differences between the U.S.
dollar and the New Israeli Shekel.

Net and Comprehensive Loss

As a result of the foregoing, Successor’s
and Predecessor’s loss totaled $5,412 thousand for the period commencing January 1, 2024 through July 23, 2024, representing an
increase of $3,991 thousand, or 280.8%, compared to Predecessor’s $1,421 thousand for the same period.

Comparison of Predecessor’s Results of Operations for the year ended December 31, 2023 and 2022

The following table
is data derived from the Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts:

|                                     |     | For the year ended 
 December,          
 31                 |  2023 |   |     |     | 2022 |
|:------------------------------------|:----|:-------------------|------:|:--|:----|:----|-----:|
|                                     |     | USD in thousands   |       |   |     |     |      |
| Research and development expenses   |     |                    |